Benz, E. 1989. Halluzinogen-unterstützte Psychotherapie. Zürich: Medical dissertation.
Berendes, M. 1979–1980. Formation of typical dynamic stages in psychotherapy before and after psychedelic drug intervention. Journal of Altered States of Consciousness 5:325–38.
Beringer, K. 1927. Der Meskalinrausch. Berlin: Springer.
Busch, A. and W. Johnson. 1950. LSD 25 as an aid in psychotherapy. Diseases of the Nervous System 11:241–43.
Chwelos, N., D. B. Blewett, C. M. Smith, and A. Hoffer. 1959. Use of d-Lysergic Acid Diethylamide in the treatment of alcoholism. Quarterly Journal of Studies on Alcohol 20:577–90.
Clark, B. 1967–1968. Some early observations on the use of Psilocybin in psychiatric patients. British Journal of Social Psychiatry 2:21–26.
Clark, J. 1970. The use of Psilocybin in a prison setting. In Psychedelics, eds.B. Aaronson and H. Osmond, 40–44. London: Hogarth Press.
Clark, W. H. 1977. Art and psychotherapy in Mexico. Art of Psychotherapy 4:41–44.
Cwynar, S. and Z. Rydzynski. 1966. Psilocybin in der Behandlung von persönlichkeitsstörungen. Activitas Nervosa Superior 8:424.
Da Fonseca, J. S., C. Cardoso, P. Salguiero and M. L. Fialho. 1965. Neurophysiological and psychological study of Psilocybin-induced modifications of visual information processing in man. In Neuro-Psychopharmacology Vol. 4, eds. D. Bente & P. B. Bradley, 315–19. Amsterdam, London, New York: Elsevier.
David, A. E. and J. David. 1961. La psilocibina, un nuevo alucinogeno, y sus posibilidades terapeuticas en psicoterapia. Acta Neuropsiquatrica Argentina 7:143–44.
Delay, J., P. Pichot and P. Nicolas-Charles. l959. Premiers essais de la psilocybine en psychiatrie. In Neuro-Psychopharmacology, eds. P. Bradley, P. Deniker and C. Radouco-Thomas, 528–31. Amsterdam, London, New York, Princeton: Elsevier.
Delay, J., P. Pichot, T. Lemperiere and A. M. Quetin. 1959. Effet therapeutique de la psilocybine sur une nevrose convulsive. Annales medico-psychologiques 117:509–15.
Delay, J., P. Pichot, T. Lemperiere, P. Nicolas-Charles and A. M. Quetin. l959. Les effets psychiques de la psilocybine et les perspectives therapeutiques. Annales medico-psychologiques 117:899–907.
Delay, J., P. Pichot, and T. Lemperiere. 1961. La Psilocybine—Ses implications therapeutiques. Le Sud Medical et Chirurgical 97:9217–24.
———. 1963. The therapeutic implications of Psilocybine. In Hallucinogenic drugs and their Psychotherapeutic Use, eds. R. Crocket, R. A. Sandison, A. Walk, 37–41. London: Lewis.
Derbolowsky, G. 1967–1968. Dealing and working with materials in groupanalysis and with “LSD-25.” British Journal of Social Psychiatry 2:67–72.
Derbolowsky, U. 1966. Psycholytische intervalltherapie mit LSD 25 oder ambulante analytische psychotherapie? Zeitschrift für Psychotherapie und medizinische Psychologie 16:33–38.
Doblin, R. 1998. Dr. Leary´s Concord Prison Experiment: A 34-year follow-up study. Journal of Psychoactive Drugs 30:419–26
Dubansky, B., M. Vyhnankova and L. Setlik. l967a. Veränderungen der ausseroptischen Sinneswahrnehmung nach Psilocybin. Activitas Nervosa Superior 9:378–79.
———. 1967b. Gleichzeitiges Vorkommen von propriozeptiven S innestäuschungen und neurologischer symptomatologie nach Psilocybin. Activitas Nervosa Superior 9:376–77.
Duche, D. 1961. Les effets de la psilocybine dans une cas d’hysterie. Semaine des hospitaux de Paris 37:3061–62.
Fernandez-cerdeno, A., A. Brugmann and A. Suarez. l967. Besonderheiten der psycholytischen Technik im Vergleich mit der psychoanalytischen. Jahrbuch für Psychologie, Psychotherapie und medizinische Anthropologie 15:274–79.
Fernandez-cerdeno, A. and H. Leuner. 1967. Das Erleben der oralen regression unter Einfluss von halluzinogenen (LSD-25 und Psilocybin). Zeitschrift für psychosomatische Medizin 11:45–54.
Fischer, R., R. M. Hill, K. Thatcher, and J. Scheib. 1970. Psilocybin-induced contraction of nearby visual space. Agents and Actions 1:190–97.
Fisher, G. 1963. Some comments concerning dosage levels of psychedelic compounds for psychotherapeutic experiences. Psychedelic Review 1:208–18.
Flores, J. R. 1966. Psicosindrome experimental con psilocybina. Revista de Neuropsiquiatria 29:45–70.
Fontana, A. E. 1961. El uso clinico de las drogas alucinogenas. Acta Neuropsiqiatrica Argentina 7:94–98.
———. Clinical use of hallucinogenic drugs. In Proceedings of the Third World Congress of Psychiatry Vol. 2., 942–44. Toronto: University of Toronto Press.
Fortes, J. R. A. 1964. Psilocibina e alcoolismo cronico: contribuciao para los estudo des efeitos somaticos e psiquicos em 30 casos. Sao Paulo: Medical dissertation.
Fortes, J. R. A., F. O. Bastos, and R. V. Arruda. 1968. Estudio comparativa de la accion psicopharmacologico del LSD-25 y de la psilocybina en los alocoholicos cronicos. In Proceedings Fourth World Congress of Psychiatry 1966 Vol. 3, ed. J. Lopez Ibor, 2010–13. Amsterdam: Excerpta Medica.
Frederking, W. 1953–1954. Über die Verwendung von Rauschdrogen (Meskalin und Lysergsäurediäthylamid) in der Psychotherapie. Psyche 7:342–64.
———. 1954. Meskalin in der psychotherapie. Medizinischer Monatsspiegel 3:5–7.
Gasser, P. 1995. Katamnestische Untersuchungen zur psycholytischen therapie. Yearbook of Cross-Cultural Medicine and Psychotherapy 1995:143–62.
Geert-Jörgensen, E., M. Hertz, K. Knudsen, and K. Kristensen. 1964. LSDtreatment: Experience gained within a three-year-period. Acta Psychiatrica Scandinavica, 373–82. Suppl. 180.
Gnirss, F. 1959. Untersuchungen mit Psilocybin, einem phantastikum aus dem amerikanischen Rauschpilz Psilocybe mexicana. Schweizer Archiv für Neurologie und Psychiatrie 84:346–48.
———. 1963. Therapie der neurosen mit phantastica. Schweizer Archiv für Neurologie, Neurochirurgie und Psychiotrie 92:234–36.
———. 1965. Neurosentherapie mit psycholytischen Stoffen. In Psychiatrische Pharmakotherapie in Klinik und Praxis, ed. F. Kielholz, 135–51. Bern, Stuttgart: Huber.
———. 1995. Personal communication.
Grof, S. 1967. The use of LSD 25 in personality diagnostics and psychotherapy of psychogenic disorders. In The Use of LSD in Psychotherapy and Alcoholism, ed. H. A. Abramson, 154–90. New York, Kansas City: Bobbs Merrill.
———. 1972–1973. LSD and the human encounter with death. Voices: The Art and Science of Psychotherapy 8:64–76.
———. 1975. Realms of the Human Unconscious. New York, N.Y.: Viking. ———.1983 LSD-Psychotherapy. Pomona, Calif.: Hunter House.
Grof, S., R. A. Soskin, W. A. Richards, and A. A. Kurland. 1973. DPT as an adjunct in psychotherapy of alcoholics. International Pharmacopsychiatry 8:104–15.
Hausner, M. 1968. Psyckolyticka psychotherapie. Activitas Nervosa Superior 10:50.
Hausner, M., and V. Dolezal. 1963. Prakticke zkusenosti s halucinogeny v psychoterapii. Ceskoslovenska Psychiatrie 54:328–35.
Hausner, M., and V. Dolezal. 1963. Group and individual therapy under LSD. Acta Psychotherapeutica et Psychosomatica 11:39–59.
Heimann, H. 1962. Zur Behandlung therapieresistenter neurosen mit modellpsychosen (Psilocybin). Schweizer Archiv für Neurologie, Neurochirurgie und Psychiatrie 89:214–20.
Hofmann, A. 1959. Abwandlungsprodukte des Psilocybin und Psilocin. Helvetica Chimica Acta 42:2073ff.
Hofmann, A., R. Heim, A. Brack, and H. Kobel. 1958. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experientia 14:107–9.
Hofmann, A., R. Heim, A. Brack, H. Kobel, A. Frey, H. Ott, T. Petrzilka, and F. Troxler. 1959. Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helvetica Chimica Acta 42:1557–72.
Hollister, L. E. 1961. Clinical, biochemical and psychologic effects of Psilocybin. Archives Internationales de Pharmacadynamie e de Therapie 130:42–52.
Hollister, L. E., R. O. Degan, and S. D. Schultz. 1962. An experimental approach to facilitation of psychotherapy by psychotomimetic drugs. Jo
urnal of Mental Science 108:99–100.
Johnsen, G. 1964. Three years experience with the use of LSD as an aid in psychotherapy. Acta Psychiatrica Skandinavica 40:383–88. Suppl. 180.
———. 1967. Indications for psycholytic treatment with different types of patients. In The Use of LSD in Psychotherapy and Alcoholism, ed. H. A. Abramson, 333–41. New York, Kansas City: Bobbs Merrill.
Keeler, M. H. 1965. Similarity of schizophrenia and the Psilocybin syndrome as determined by objective methods. International Journal of Neuropsychiatry 1:630–34.
Kristensen, K. K. 1963. Kliniske erfaringer med psilocybin. Nordisk Psykiatrisk Tidsskrift 17:177–82.
LaBarre, W. 1938. The Peyote Cult. New Haven.
Ladewig, D. 1994. Conclusions, with special regard to clinical aspects. In 50 Years of LSD. Current Status and Perspectives of Hallucinogens, eds. A. Pletscher and D. Ladewig, 223–28. New York, London: Parthenon.
Leary, T. 1962. How to Change Behavior. In Clinical Psychology, ed. G. S. Nielsen, 50-68. Kopenhagen.
———. 1964. The religious experience: Its production and interpretation. Psychedelic Review 1:324–46.
———. 1969. The effects of consciousness-expanding drugs on prisoner rehabilitation. Psychedelic Review 10:29–44.
Leary, T., R. Alpert, and R. Metzner. 1964. The Psychedelic Experience. New York: University Books.
Leary, T., G. H. Litwin, and R. Metzner. 1963. Reactions to Psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease 137:561–73.
Leary, T., and R. Metzner. 1967–1968. Use of psychedelic drugs in prisoner rehabilitation. British Journal of Social Psychiatry 2:27–51.
Leary, T., R. Metzner, M. Presnell, G. Weil, R. Schwitzgebel, and S. Kinne. 1965. A new behavior change program using Psilocybin. Psychotherapy: Theory, Research and Practice 2:61–72.
Leuner, H. 1959. Psychotherapie in modellpsychosen. In Kritische Psychotherapie, ed. E. Speer, 94–102. München: J. F. Lehmanns.
———. 1960. Über psychopathologische schlüsselfunktionen in der modellpsychose. Medicina Experimentalis 2:227–32.
———. 1961. Psychophysische korrelationen unter der einwirkung von psycholytika (LSD Psilocybin und ähnl.). Medicina Experimentalis 5:209–14.
———. l962a. Die experimentelle Psychose. Berlin, Göttingen, Heidelberg: Springer.
———. 1962b. Ergebnisse und probleme der psychotherapie mit Hilfe von LSD-25 und verwandten substanzen. Psychiat. Neurol. 143:379–91.
———. 1963. Die psycholytische therapie: KIinische psychotherapie mit Hilfe von LSD-25 und verwandten substanzen. Zeitschrift für Psychotherapie und medizinische Psychologie 13:57–64.
———. 1966. Psychotherapie mit Hilfe von halluzinogenen. Arzneimittelforschung 16:253–55.
———. 1967. Present status of psycholytic therapy and its possibilities. In The Use of LSD in Psychotherapy and Alcoholism, ed. H. A. Abramson, 101–16. New York, Kansas City: Bobbs Merrill.
———. 1968. Ist die Verwendung von LSD-25 für die experimentelle psychiatrie und in der psychotherapie heute noch vertretbar? Nervenarzt 39:356–60.
———. 1971. Halluzinogene in der psychotherapie. Pharmakopsychiatrie—Neuro-Psychopharmakologie 4:333–51.
———. 1981. Halluzinogene. Bern, Stuttgart, Wien: Huber.
———. 1987. Die psycholytische therapie: Durch halluzinogene unterstützte tiefenpsychologische psychotherapie. In Ethnopsychotherapie, eds. A. Dittrich, and C. Scharfetter, 151–60. Stuttgart: Enke.
———. 1994. Hallucinogens as an aid in pychotherapy: Basic principles and results. In 50 Years of LSD. Current Status and Perspectives of Hallucinogens, eds. A. Pletscher, and D. Ladewig, 175–90. New York, London: Parthenon.
———. 1995. Personal communication.
Leuner, H., and G. Baer. 1965. Two new short-acting hallucinogens of the Psilocybin group. In Neuro-Psychopharmacology Vol. 4, eds. D. Bente, and P. B. Bradley, 471–73. Amsterdam, London, New York: Elsevier.
Leuner, H., and H. Holfeld. 1964. Psycholysis—Psychotherapy under the influence of hallucinogens. Physicians Panorama 2:13–16.
Ling, T. M., and J. Buckman. 1963. Lysergic Acid (LSD-25) & Ritalin in the Treatment of Neuroses. Sidcup, Kent: Lombarde Press.
Lipp, F. 1990. Mixed concepts and uses of entheogenic mushrooms. In The Sacred Mushroom Seeker, ed. T. Riedlinger, 151–60. Portland, Ore.: Discorides Press.
Malitz, S., H. Esecover, B. Wilkens, and P. H. Hoch. 1960. Some observations on Psilocybin, a new hallucinogen in volunteer subjects. Comprehensive Psychiatry 1:8–17.
Mascher, E. 1966. Katamnestische Untersuchung von Ergebnissen der psycholytischen Therapie. Göttingen: Medical dissertation.
Massoni, R. S., and F. Lebensohn. 1964. Las drogas alucinogenas: su importancia en psicoterapia asistencial. Acta psiquiatrica y psicologica America latina 10:128–32.
Metzner, R., and Editors of Psychedelic Review. 1963. The subjective aftereffects of psychedelic experiences: A summary of four recent questionnaire studies. Psychedelic Review 1:18–26.
Metzner, R., G. Litwin, and G. M. Weil. 1965. The relation of expectation and mood to Psilocybin reactions: A questionnaire study. Psychedelic Review 5:339.
Metzner, R. 1998. Reflections on the Concord Prison Project and the follow-up study. Journal of Psychoactive Drugs 30:427–28.
Nieto Gomez, D. 1962. Psicosis experimentales con Psilocibina. Neurologia, Neurocirurgia, Psiquiatria 4.
Pahnke, W. N. 1962. Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness. Cambridge, Mass.: Philosophical dissertation.
Passie, T. 1985. Field observations in Mexiko.
———. 1987. Field observations in Mexiko.
———. 1995a. Ausrichtungen, methoden und ergebnisse früher meskalinforschungen im deutschsprachigen Raum. Yearbook of the European College for the Study of Consciousness 1993–1994:103–11.
———. 1995b. Die psycholyse in den skandinavischen Ländern. Ein historischer Überblick. Yearbook of Cross-Cultural Medicine and Psychotherapy 1995:183–220.
———. 1995c. Psilocybin in der modernen psychotherapie. Curare 18:131–52.
Passie, T., J. Seifert, U. Schneider, and H. M. Emrich. 2002. The pharmacology of Psilocybin. Addiction Biology 7:357–64.
Perez de Francisco, C. 1964. Psicosis experimentales con psilocybina y LSD. Mexico City: Medical dissertation.
Pletscher, A., and D. Ladewig, eds. 1994. 50 Years of LSD. Current Status and Perspectives of Hallucinogens. New York, London: Parthenon.
Quetin, A. M. 1960. La psilocybine en psychiatrie clinique et experimentale. Paris: Medical dissertation.
Reda, G., G. Vella, I. Cancrini, and E. D’Agostino. 1964. Studio clinico e psicopatologico della psilocibina. Rivista sperimentale di freniatria e medicina legale delle alientazioni mentali 88:7–76.
Rinkel, M., A. DiMascio, A. Robey, and C. Atwell. 1961. Personality patterns and reaction to Psilocybin. In Neuro-Psychopharmacology Vol. 2, ed. P. B. Bradley, 273–79. Amsterdam: Elsevier.
Roquet, S., and P. Favreau. 1981. Los alucinogenos de Ia concepcion indigena a una nueva psicoterapia. México D.F.: Ediciones Prisma.
Roquet, S., P. Favreau, R. Ocana, and M. R. Velasco. 1975. La existencial a través de psicodyslepticos: una nueva Psicoterapia. Mexico City: lnstituto de psicosintesis.
Rosenbohm, A. 1991. Halluzinogene Drogen im Schamanismus. Berlin: Reimer
Rydzynski, Z., and W. Gruszczynski. 1978. Treatment of alcoholism with psychotomimetic drugs: A follow-up study. Activitas Nervosa Superior 20:81–82.
Salguiero, E. G. 1964. A psicose experimental pela psilocibina: estudio clinicolabortorial em voluntarios humanos. Lissabon: Inquerito.
Sandison, R. A. 1954. Psychological aspects of the LSD treatment of the neurosis. Journal of Mental Science 100:508–18.
———. 1959. The role of psychotropic drugs in individual therapy. Bulletin of the World He
alth Organization 21:495–503.
Sandison, R. A., and A. Spencer. 1954. The therapeutic value of Lysergic Acid Diethylamide in mental illness. Journal of Mental Science 100:491–507.
Sandison, R. A., A. Spencer, and J. Whitelaw. 1957. Further studies in the therapeutic value of Lysergic Acid Diethylamide in mental illness. Journal of Mental Science 103:332–42.
Savage, C. 1962. LSD, alcoholism and transcendence. Journal of Nervous and Mental Disease 135:429–35.
Savage, C., and S. Wolf. 1967. An outline of psychedelic therapy. In Neuro-Psycho-Pharmacology, ed. H. Brill, 405–10. Amsterdam: Excerpta Medica.
Schulz-Wittner, G. 1989. Mit psychoaktiven substanzen unterstützte psychotherapie bei negativ prognostizierten patienten: Neue katamnestische Ergebnisse. Göttingen: Medical dissertation.
Sercl, M., J. Kovarik, and O. Jaros. 1961. Klinische erfahrungen mit Psilocybin (CY-39 Sandoz). Psychiat. Neurol. 142:137–46.
Sherwood, J. N., M. Stolaroff, and W. W. Harman. 1962. The psychedelic experience—A new concept in psychotherapy. Journal of Neuropsychiatry 4:69–80.
Soskin, R. A. 1975. Dipropyltryptamine in psychotherapy. Current Psychiatric Therapies 15:147–56.
Soskin, R. A., S. Grof, and W. A. Richards. 1973. Low doses of Dipropyltryptamlne in psychotherapy. Archives of General Psychiatry 28:817–21.
Steinegger, E., and H. Heimann. 1966. Pharmakochemie und psychische Wirkung von drei mexikanischen zauberdrogen. Mitteilungen der Naturforschenden Gesellschaft in Bern 23:83–99.
Stevenin, L., and J. C. Benoit. 1962. L’utilisation des medicaments psychotropes en psychotherapie. Encephale 51:420–59.
Stoll, W. A. 1947. Lysergsäure-diätlhylamid, ein phantastikum aus der mutterkorngruppe. Schweizer Archiv für Neurologie und Psychiatrie 60:279–323.
Styk, J. 1994. Personal communication.
Swain, F. 1963. Four Psilocybin experiences. Psychedelic Review 2:219–43.
Vernet, I. 1960. Actions psychologique et therapeutique de la psilocybine. Medecine et Hygiene 18:420.
Villoldo, A. 1977. An introduction to the psychedelic psychotherapy of
Salvador Roquet. Journal of Humanistic Psychology 17:45–58.
Sacred Mushroom of Visions Page 15
